
Work Here?
Work Here?
Work Here?
1) What CHOP does: Children’s Hospital of Philadelphia provides pediatric healthcare services and supports international families through its Global Patient Services team to access top-tier medical care for children. 2) How it works: CHOP offers a wide range of pediatric specialties and coordinates care for international patients, including consultations, treatments, and specialized procedures, backed by a network of clinicians, hospitals, and patient-support services. 3) How it differs: CHOP emphasizes its focus on pediatric medicine, global patient access, and comprehensive family-centered care, backed by renowned clinical programs and a global outreach approach. 4) Goal: To deliver high-quality, specialized medical care for children worldwide and advance pediatric medicine through collaboration, research, and education.
Industries
Healthcare
Company Size
10,001+
Company Stage
Grant
Total Funding
$16.4M
Headquarters
Philadelphia, Pennsylvania
Founded
1855
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$16.4M
Above
Industry Average
Funded Over
4 Rounds
Health Insurance
Dental Insurance
Vision Insurance
Paid Vacation
Paid Holidays
PTO/vacation
Remote Work Options
Flexibl e Work Hours
Unlimited Paid Time Off
401(k) Retirement Plan
401(k) Company Match
Wellness Program
Mental Health Support
Gym Membership
Conference Attendance Budget
Professional Development Budget
Stock Options
Company Equity
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Parental Leave
Childcare Support
Phone/Internet Stipend
Home Office Stipend
John F. Brandsema, MD, on the real-world use of givinostat in DMD. The child neurologist at Children's Hospital of Philadelphia discussed long-term givinostat safety for Duchenne at MDA's 2026 conference. This interview was originally published on its sister site, "We're all enthusiastic in the Duchenne community that we have more and more options to consider for treatment of the disease. We are always more hopeful about medications that have proven efficacy in trial, like givinostat." Givinostat (Duvyzat; Italfarmaco SpA), an oral histone deacetylase inhibitor granted FDA approval for Duchenne muscular dystrophy (DMD), was the subject of a safety and efficacy evaluation in the now-completed phase 3 EPIDYS trial (NCT02851797).[1] The trial's open-label extension (OLE; NCT03373968), which is still underway, continues to assess the long-term safety, tolerability, and efficacy of givinostat among patients who either finished or were screened but not randomized in previous studies. An interim analysis presented at, held March 9-11 in Orlando, Florida, by lead author John F. Brandsema, MD, a child neurologist at Children's Hospital of Philadelphia, sought to characterize the safety outcomes observed thus far in the OLE population.[2] Through December 31, 2023, a total of 207 patients had been enrolled - among them those previously treated with givinostat (n = 119), those who had received placebo (delayed givinostat; n = 58), and treatment-naïve patients (n = 30). All participants were given weight-based givinostat alongside corticosteroids, with mean exposure surpassing 1,000 days across all groups. Almost all patients (98.1%) experienced at least 1 treatment-emergent adverse event (AE), most of which were mild to moderate in severity. Frequently reported AEs included gastrointestinal symptoms, falls, thrombocytopenia, and elevated triglycerides, with some variation noted between groups. Taken together, these findings aligned with givinostat's known safety profile, and no new safety signals were identified. At the conference, Brandsema spoke with CGTLive(R)'s sister site NeurologyLive(R) to emphasize the importance of interpreting long-term safety data alongside real-world clinical experience. He noted that although givinostat has demonstrated efficacy and can be used in combination with other treatments, clinicians should remain attentive to tolerability considerations. Available evidence suggests that most AEs are manageable and may be addressed with dose adjustments without compromising treatment effect. However, he highlighted the need for continued investigation into potential late-onset laboratory abnormalities, cardiac safety, and outcomes in broader patient population. REFERENCES 1. FDA approves nonsteroidal treatment for Duchenne muscular dystrophy. FDA. News release. March 21, 2024. Accessed March 18, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-nonsteroidal-treatment-duchenne-muscular-dystrophy 2. Brandsema J, acsadi G, alessi F, et al. Long-Term safety of givinostat in patients with Duchenne muscular dystrophy: interim results from an open-label extension study. Presented at: MDA clinical & scientific conference; March 8-11, 2026; Orlando, Florida. Abstract 51. Stay at the forefront of cutting-edge science with CGT - your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Labcorp, CHOP to develop, commercialize specialty pediatric diagnostics. NEW YORK - Laboratory Corporation of America and Children's Hospital of Philadelphia (CHOP) on Monday announced a strategic collaboration to accelerate the development of and access to specialized pediatric diagnostics. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month
1 killed, 2 missing after parking garage under-construction in philly partially collapses. A partial collapse at a parking garage under construction in Philadelphia has left one person dead and two others still missing, as emergency crews continue a difficult and time-sensitive search operation. The incident unfolded around 2:17 p.m. on April 8 at a job site in the Grays Ferry neighborhood near 30th Street and Grays Ferry Avenue. The structure, a seven-story garage being built for the Children's Hospital of Philadelphia, suffered a major failure during construction work. According to city officials, the collapse began when a precast concrete roof section gave way while being installed. "After placement, a precast roof segment failed and fell to the level below, literally triggering a progressive collapse of connected sections across all seven levels," said Mayor Cherelle Parker. The failure caused a chain reaction, bringing down large portions of the structure, particularly along the stairwell on the 30th Street side. Emergency responders quickly arrived and rescued three individuals from the debris. All were taken to a hospital, where one later died from critical injuries. The other two were treated and released. Officials say two additional workers remain unaccounted for. Rescue operations have proven especially challenging due to the building's instability. Crews have had to pause at times to allow engineers to assess and stabilize the structure before continuing. Fire Commissioner Jeffrey Thompson emphasized that the process will be slow and deliberate to protect both victims and first responders. "We will not rest until everyone is accounted for from this tragedy," Parker said, underscoring the city's commitment to the ongoing effort. Authorities confirmed that all required permits for the project had been issued and inspections were current. However, some components - like the precast concrete sections - were manufactured and installed off-site, falling under specialized inspection protocols rather than standard city oversight. The collapse has led to widespread disruptions in the surrounding area. A stretch of Grays Ferry Avenue between 29th and 33rd streets remains closed, and residents and businesses nearby have been advised to expect ongoing interruptions with no clear timeline for reopening. In a statement, the Children's Hospital of Philadelphia said, "We are prioritizing the safety of the construction workers at this time and working closely with the City of Philadelphia and our construction partners." Investigations into the cause of the collapse are underway, with city agencies and federal safety officials working to determine what went wrong. For now, the focus remains on carefully securing the site and continuing the search for the missing workers in what officials describe as a complex and ongoing operation.
CHOP Cardiac Center to open pediatric cardiology site in Somerset. The Cardiac Center at Children's Hospital of Philadelphia will open a new outpatient location in Somerset in April. According to a March 23 announcement from Philadelphia-based CHOP, the new center will offer: * Cardiology clinic visits for new and existing patients * Non-invasive testing such as EKG, IAC accredited pediatric echocardiograms (ECHO) and Holter tests * Fetal echocardiography * Access to expert fetal cardiology services and consultation in partnership with CHOP's Fetal Heart Program Located at 61 Veronica Ave., CHOP Cardiac Center, Somerset, will be staffed by clinicians and staff who have served the community for more than 20 years. Patients will also have access to free parking at the site. Meet the Somerset cardiology team: * Dr. Michele Cohen Cohen is a board-certified attending cardiologist. She's also an assistant professor of pediatrics at the Perelman School of Medicine at the University of Pennsylvania, according to her CHOP bio. * Dr. Sumekala Nadaraj Nadaraj also is an attending cardiologist with special interests in fetal echocardiography and pediatric cardiology. Her areas of expertise are epidemiology, fetal echocardiography and pediatric cardiology. * Dr. Chandni Patel Patel also is an attending cardiologist as well as a clinical assistant professor of pediatrics at Penn. * Dr. Ezequiel Sagray Fluent in Spanish, Sagray is a pediatric cardiologist. "We are excited to continue providing CHOP's world-class pediatric cardiac services in a convenient location for families in central New Jersey," said Dr. Vivek Allada, medical director of Outpatient and Community Cardiology at CHOP. "As the top-ranked pediatric cardiology program in the region, we remain committed to delivering the highest quality care closer to home for our New Jersey patients and families." CHOP's additional Garden State Cardiac Centers are located in Voorhees, Plainsboro and Mays Landing. Last year, CHOP acquired a vacant AMC Theatres in Hamilton with plans to redevelop the site as a pediatric medical center.
Children's Hospital of Philadelphia will open a new outpatient cardiac centre in Somerset, New Jersey, in April 2026. Located at 61 Veronica Avenue, the facility will provide cardiology clinic visits, non-invasive testing including EKG and paediatric echocardiograms, and foetal echocardiography services. The centre will be staffed by CHOP clinicians who have served the New Jersey community for over 20 years. This expansion is part of CHOP's broader network of 16 outpatient locations across Pennsylvania and New Jersey, including existing facilities in Voorhees, Plainsboro and Mays Landing. CHOP operates one of the largest outpatient cardiology services in the United States and partners with more than 30 community hospitals in the region.
Find jobs on Simplify and start your career today
Industries
Healthcare
Company Size
10,001+
Company Stage
Grant
Total Funding
$16.4M
Headquarters
Philadelphia, Pennsylvania
Founded
1855
Find jobs on Simplify and start your career today